Guiyuan Li1, Shengming Yi1, Fan Yang2, Yongxin Zhou3, Qiang Ji3, Jianzhi Cai3, Yunqing Mei3. 1. Department of Oncology, Tongji Hospital, Tongji University School of Medicine Shanghai, China. 2. Department of Clinical Laboratory Medicine, Tongji Hospital, Tongji University School of Medicine Shanghai, China. 3. Department of Thoracic Cardiovascular Surgery, Tongji Hospital, Tongji University School of Medicine Shanghai, China.
Abstract
BACKGROUND: To identify mutant genes with high-frequency-risk-expression between lung adenocarcinoma and normal samples. METHODS: The ribonucleic acid RNA-Seq data GSE34914 and GSE37765 were downloaded from the Gene Expression Omnibus database, including 12 lung adenocarcinoma samples and six controls. All RNA-Seq reads were processed and the gene-expression level was calculated. Single nucleotide variation (SNV) was analyzed and the locations of mutant sites were recorded. In addition, the frequency and risk-level of mutant genes were calculated. Gene Ontology (GO) functional analysis was performed. The reported cancer genes were searched in tumor suppressor genes, Cancer Genes, and the Catalogue of Somatic Mutations in Cancer (COSMIC) database. RESULTS: The SNV annotations of somatic mutation sites showed that 70% of mutation sites in the exon region occurred in the coding sequence (CDS). Thyroid hormone receptor interactor (TRIP)12 was identified with the highest frequency. A total of 118 mutant genes with high frequency and high-risk were selected and significantly enriched into several GO terms. No base mutation of cyclin C (CCNC) or RAB11A was recorded. At fragments per kilobase per million reads (FPKM) ≥ 56.5, reported tumor suppressor genes catenin (cadherin-associated protein), delta (CTNND)1, dual specificity phosphatase (DUSP)6, malate dehydrogenase (MDH)1 and RNA binding motif protein (RBM)5, were identified. Notably, signal transducer and activator of transcription 2 (STAT2) was the only transcription factor (TF) with high-risk mutation and its expression was detected. CONCLUSION: For the mutant genes with high-frequency-risk-expression, CTNND1, DUSP6, MDH1 and RBM5 were identified. TRIP12 might be a potential cancer-related gene, and expression of TF STAT2 with high-risk was detected. These mutant gene candidates might promote the development of lung adenocarcinoma and provide new diagnostic potential targets for treatment.
BACKGROUND: To identify mutant genes with high-frequency-risk-expression between lung adenocarcinoma and normal samples. METHODS: The ribonucleic acid RNA-Seq data GSE34914 and GSE37765 were downloaded from the Gene Expression Omnibus database, including 12 lung adenocarcinoma samples and six controls. All RNA-Seq reads were processed and the gene-expression level was calculated. Single nucleotide variation (SNV) was analyzed and the locations of mutant sites were recorded. In addition, the frequency and risk-level of mutant genes were calculated. Gene Ontology (GO) functional analysis was performed. The reported cancer genes were searched in tumor suppressor genes, Cancer Genes, and the Catalogue of Somatic Mutations in Cancer (COSMIC) database. RESULTS: The SNV annotations of somatic mutation sites showed that 70% of mutation sites in the exon region occurred in the coding sequence (CDS). Thyroid hormone receptor interactor (TRIP)12 was identified with the highest frequency. A total of 118 mutant genes with high frequency and high-risk were selected and significantly enriched into several GO terms. No base mutation of cyclin C (CCNC) or RAB11A was recorded. At fragments per kilobase per million reads (FPKM) ≥ 56.5, reported tumor suppressor genes catenin (cadherin-associated protein), delta (CTNND)1, dual specificity phosphatase (DUSP)6, malate dehydrogenase (MDH)1 and RNA binding motif protein (RBM)5, were identified. Notably, signal transducer and activator of transcription 2 (STAT2) was the only transcription factor (TF) with high-risk mutation and its expression was detected. CONCLUSION: For the mutant genes with high-frequency-risk-expression, CTNND1, DUSP6, MDH1 and RBM5 were identified. TRIP12 might be a potential cancer-related gene, and expression of TF STAT2 with high-risk was detected. These mutant gene candidates might promote the development of lung adenocarcinoma and provide new diagnostic potential targets for treatment.
Entities:
Keywords:
High expression; RNA-Seq; high frequency; high-risk; lung adenocarcinoma; mutant gene
Authors: Elizabeth T Cirulli; Abanish Singh; Kevin V Shianna; Dongliang Ge; Jason P Smith; Jessica M Maia; Erin L Heinzen; James J Goedert; David B Goldstein Journal: Genome Biol Date: 2010-05-28 Impact factor: 13.583
Authors: Juliana J Oh; Ali Razfar; Idolina Delgado; Rebecca A Reed; Anna Malkina; Baher Boctor; Dennis J Slamon Journal: Cancer Res Date: 2006-04-01 Impact factor: 12.701
Authors: Stephan Singer; Mona Malz; Esther Herpel; Arne Warth; Michaela Bissinger; Martina Keith; Thomas Muley; Michael Meister; Hans Hoffmann; Roland Penzel; Georg Gdynia; Volker Ehemann; Philipp Albert Schnabel; Ruprecht Kuner; Peter Huber; Peter Schirmacher; Kai Breuhahn Journal: Cancer Res Date: 2009-03-03 Impact factor: 12.701
Authors: Zhenfeng Zhang; Susumu Kobayashi; Alain C Borczuk; Rom S Leidner; Thomas Laframboise; Alan D Levine; Balazs Halmos Journal: Carcinogenesis Date: 2010-01-22 Impact factor: 4.741
Authors: Jacob Shujui Hsu; Ruizhong Zhang; Fanny Yeung; Clara S M Tang; John K L Wong; Man-Ting So; Huimin Xia; Pak Sham; Paul K Tam; Miaoxin Li; Kenneth K Y Wong; Maria-Mercè Garcia-Barcelo Journal: ERJ Open Res Date: 2019-02-04